Updated on 10 June 2013
Dr Michelle Carr, director, Telezon, Australia
Australia-based Telezon Limited's CoreIT and SoloFlow Reconstitution Needle technology have already made a mark for itself in the market that is dominated by steel needles. Led by its director, Dr Michelle Carr, the company has already secured two commercial arrangements for sale and supply of its SoloFlow Non-Injection Needle in India and is currently seeking investment in order to accelerate commercialization of its products and technologies in the global market.
In an interview with BioSpectrum, Dr Carr highlights the key technology differentiator of Victoria-based Telezon's portfolio and shares the firm's market agenda.
How has the market reacted to the launch of Telezon's CoreIT Technology and the SoloFlow Reconstitution Needle?
CoreIT technology and SoloFlow Reconstitution Needle have both been very well received by the market. CoreIT is an advanced moulding technology that enables plastic cannula to be precision moulded and SoloFlow Needle is used only for the draw-up or mixing drugs.
We have found that market interest across our portfolio has significantly increased since the launch. Our portfolio includes PolyDermic (plastic hypodermic or injection needle), Blunt SoloFlow (blunt draw-up/application needle) and a unique range of drug delivery needle solutions. This technology offers companies the opportunity to reduce processing time without compromising on quality.
How are the products positioned in the market?
Dr Carr: So far, the needle market has been dominated by steel needles that cater to drug delivery and drug reconstitution. Among our products, Telezon's SoloFlow has been positioned in the market against steel needles in certain applications. Although the market is tightly held by steel needles, we have noticed that there is a demand in some markets for cheaper, easy-to-use and disposable, safer alternatives to steel.